- cafead   Feb 09, 2021 at 11:42: AM
via Veru yesterday heralded a win in a small trial of its oral microtubule inhibitor VERU-111 in hospitalised Covid-19 patients, and consequently enjoyed a 28% share price bump. But a close read of the data reveals that the findings are not quite as rosy as the company claims.
article source
article source